局部晚期胰腺癌患者的放化疗：这仍是一个悬而未决的问题吗？
Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?
作者信息
Sawicka Emilia, Mirończuk Anna, Wojtukiewicz Marek Z, Sierko Ewa
机构信息
Scientific Students Association affiliated with the Department of Oncology, Medical University of Bialystok, Poland.
Department of Oncology, Medical University of Bialystok, Poland; Comprehensive Cancer Center, Bialystok, Poland.
出版信息
Contemp Oncol (Pozn). 2016;20(2):102-8. doi: 10.5114/wo.2016.60066. Epub 2016 Jun 14.
Abstract
Operable pancreatic cancer is characterized by a high risk of recurrence. Efforts are made to incorporate new therapies. Throughout the world there is a lack of uniform recommendations concerning the adjuvant treatment of pancreatic cancer patients, due to confusing evidence-based data. The patients recruited to clinical trials differ from the population of patients treated in everyday practice. These differences have an influence on tolerance of treatment, toxicity and results of therapy. The decision on administration of adjuvant treatment is made individually and differs from center to center. A review of the literature concerning both results and tolerance of postoperative chemoradiotherapy of pancreatic cancer patients is presented.
摘要
可手术切除的胰腺癌具有高复发风险。人们致力于纳入新的治疗方法。由于循证数据令人困惑，全球对于胰腺癌患者的辅助治疗缺乏统一的建议。参加临床试验的患者与日常临床治疗的患者群体有所不同。这些差异对治疗耐受性、毒性和治疗结果均有影响。辅助治疗的决策是个体化的，且各中心之间存在差异。本文对有关胰腺癌患者术后放化疗的结果及耐受性的文献进行了综述。
相似文献
1
Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?局部晚期胰腺癌患者的放化疗：这仍是一个悬而未决的问题吗？
Contemp Oncol (Pozn). 2016;20(2):102-8. doi: 10.5114/wo.2016.60066. Epub 2016 Jun 14.
2
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.奥沙利铂联合氟尿嘧啶为基础的术前放化疗和局部进展期直肠癌术后化疗（德国 CAO/ARO/AIO-04 研究）：多中心、开放标签、随机、III 期临床试验的最终结果。
Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.
3
[Adjuvant Chemotherapy after Surgery for Pancreatic Cancer].[胰腺癌手术后的辅助化疗]
Gan To Kagaku Ryoho. 2016 Feb;43(2):160-4.
4
FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.基于 FOLFIRINOX 的新辅助放化疗治疗交界性和局部进展期胰腺癌：来自一家三级中心的初步研究。
Dig Liver Dis. 2019 Jul;51(7):1043-1049. doi: 10.1016/j.dld.2019.03.004. Epub 2019 Apr 15.
5
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.奥沙利铂、氟尿嘧啶和亚叶酸钙与氟尿嘧啶和亚叶酸钙作为术前放化疗后局部进展期直肠癌的辅助化疗（ADORE）：一项开放标签、多中心、2 期、随机对照临床试验。
Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4.
6
[Chemoradiotherapy for Locally Advanced Pancreatic Cancer].[局部晚期胰腺癌的放化疗]
Gan To Kagaku Ryoho. 2015 Oct;42(10):1152-5.
7
[The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review].[放化疗在局部晚期胰腺癌治疗中的价值：系统评价]
Bull Cancer. 2008 Nov;95(11):1116-30. doi: 10.1684/bdc.2008.0749.
8
Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.局部晚期胰腺癌的术前化疗、放疗及手术切除
Arch Surg. 2000 Jan;135(1):81-7; discussion 88. doi: 10.1001/archsurg.135.1.81.
9
Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.新辅助放化疗和手术治疗局部进展期直肠癌后的奥沙利铂/氟尿嘧啶为基础的辅助化疗：随机对照试验的系统评价和荟萃分析。
Colorectal Dis. 2016 Aug;18(8):763-72. doi: 10.1111/codi.13381.
10
Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy.局部晚期胰腺癌：根治性放化疗的作用
Clin Oncol (R Coll Radiol). 2014 Sep;26(9):560-8. doi: 10.1016/j.clon.2014.06.002. Epub 2014 Jul 4.
引用本文的文献
1
D-Pinitol treatment induced the apoptosis in human leukemia MOLT-4 cells by improved apoptotic signaling pathway.D-松醇处理通过改善凋亡信号通路诱导人白血病MOLT-4细胞凋亡。
Saudi J Biol Sci. 2020 Aug;27(8):2134-2138. doi: 10.1016/j.sjbs.2020.06.034. Epub 2020 Jun 25.
2
Expansion of Circulating Tumor Cells from Patients with Locally Advanced Pancreatic Cancer Enable Patient Derived Xenografts and Functional Studies for Personalized Medicine.从局部晚期胰腺癌患者中扩增循环肿瘤细胞可实现患者来源的异种移植及个性化医疗的功能研究。
Cancers (Basel). 2020 Apr 20;12(4):1011. doi: 10.3390/cancers12041011.
3
"HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.“HEATPAC”-局部晚期胰腺癌同期热化疗与单纯化疗的 II 期随机研究。
Radiat Oncol. 2017 Nov 21;12(1):183. doi: 10.1186/s13014-017-0923-8.
4
Inhibitory effect of Ginkgol C17:1 on the biological behavior of tumor cells.银杏内酯C17:1对肿瘤细胞生物学行为的抑制作用。
Oncol Lett. 2017 Mar;13(3):1873-1879. doi: 10.3892/ol.2017.5664. Epub 2017 Feb 1.
5
Quantitative Proteomic Analysis of Serum Exosomes from Patients with Locally Advanced Pancreatic Cancer Undergoing Chemoradiotherapy.接受放化疗的局部晚期胰腺癌患者血清外泌体的定量蛋白质组学分析
J Proteome Res. 2017 Apr 7;16(4):1763-1772. doi: 10.1021/acs.jproteome.7b00024. Epub 2017 Mar 8.
本文引用的文献
1
Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens.早期可切除胰腺癌患者的生存结局——吉西他滨和5-氟尿嘧啶化疗及放化疗方案的比较
Int J Clin Pract. 2014 May;68(5):578-89. doi: 10.1111/ijcp.12353. Epub 2014 Jan 29.
2
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.吉西他滨辅助化疗与可切除胰腺癌患者长期结局：CONKO-001 随机试验。
JAMA. 2013 Oct 9;310(14):1473-81. doi: 10.1001/jama.2013.279201.
3
Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis.辅助治疗切除的胰腺腺癌：系统评价和网络荟萃分析。
Lancet Oncol. 2013 Oct;14(11):1095-1103. doi: 10.1016/S1470-2045(13)70388-7. Epub 2013 Sep 12.
4
Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis.吉西他滨辅助治疗可切除胰腺癌：一项荟萃分析。
Am J Clin Oncol. 2015 Jun;38(3):322-5. doi: 10.1097/COC.0b013e3182a46782.
5
Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.胰腺癌手术后吉西他滨加 S-1 辅助化疗的长期结果。
J Surg Oncol. 2012 Aug 1;106(2):174-80. doi: 10.1002/jso.23068. Epub 2012 Feb 13.
6
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.基于氟尿嘧啶的放化疗联合吉西他滨或氟尿嘧啶化疗治疗胰腺腺癌切除术后：美国 Intergroup/RTOG 9704 三期临床试验的 5 年分析。
Ann Surg Oncol. 2011 May;18(5):1319-26. doi: 10.1245/s10434-011-1630-6. Epub 2011 Mar 10.
7
8
Current status of adjuvant therapy for pancreatic cancer.胰腺癌辅助治疗的现状。
Oncologist. 2010;15(11):1205-13. doi: 10.1634/theoncologist.2010-0121. Epub 2010 Nov 2.
9
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.根治性切除术后胰腺癌单用吉西他滨与吉西他滨为基础的放化疗的辅助治疗：一项随机 EORTC-40013-22012/FFCD-9203/GERCOR Ⅱ期研究。
J Clin Oncol. 2010 Oct 10;28(29):4450-6. doi: 10.1200/JCO.2010.30.3446. Epub 2010 Sep 13.
10
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.胰腺癌的辅助放化疗：约翰霍普金斯医院-梅奥诊所合作研究。
Ann Surg Oncol. 2010 Apr;17(4):981-90. doi: 10.1245/s10434-009-0743-7. Epub 2010 Jan 20.
Zotero 插件